GT BIOPHARMA, INC.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $17.8M | $7.3M |
| Jun 2022 | — | $15.4M | $5.4M |
| Sep 2022 | — | $16.0M | $2.5M |
| Dec 2022 | — | $11.7M | $5.7M |
| Mar 2023 | — | $13.1M | $2.0M |
| Jun 2023 | — | $11.8M | $2.8M |
| Sep 2023 | — | $10.0M | $2.6M |
| Dec 2023 | — | $7.5M | $1.1M |
| Mar 2024 | — | $5.3M | $2.0M |
| Jun 2024 | — | $5.5M | $9.2M |
| Sep 2024 | — | $2.1M | $6.4M |
| Dec 2024 | — | $-1.7M | $4.0M |
| Mar 2025 | — | $-980.0K | $2.4M |
| Jun 2025 | — | $-25.9M | $5.2M |
| Sep 2025 | — | $3.0M | $2.5M |
| Dec 2025 | — | $5.8M | $6.8M |
| Mar 2026 | — | $7.6M | $8.9M |
| Jun 2026 | — | $3.6M | $5.0M |